The short answer
Adherence describes whether treatment is taken as intended; persistence describes whether it is continued over time. Dziewierz and colleagues reviewed international real-world evidence on both for GLP-1-based therapies in Nutrients in May 2026.
Key facts
- Adherence
- Taking treatment as intended
- Persistence
- Continuing over time
- 2026 review
- Dziewierz (PMID 42280404)
- Earlier real-world work
- Mody 2018 (PMID 29271258)
- Why it matters
- Decides whether trial results generalise
- Connected concept
- Treatment-policy estimand
Two words that are not synonyms
Adherence asks whether someone takes a treatment as directed while they are on it. Persistence asks whether they are still on it at all after some period. A person can be perfectly adherent for three months and then stop, which is good adherence and poor persistence. Conflating them obscures which problem a population actually has.
Why persistence is the harder problem here
Obesity is chronic, so benefit depends on continued treatment, and stopping is followed by weight regain. That makes persistence not merely desirable but the condition on which the entire benefit rests. A therapy with excellent efficacy and poor persistence delivers much less across a population than its trial figures suggest.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why trials systematically overstate what a population will see
Trial participants are selected, monitored, supported and reminded, and receive treatment free of charge. None of that applies in routine care. The gap this produces is the difference between efficacy (what a drug does under trial conditions) and effectiveness, what it does in practice, and it is why the two are given separate names.
The direct link to estimands
This is the same distinction the efficacy and treatment-policy estimands formalise. The efficacy estimand describes what happens if everyone adheres; the treatment-policy estimand counts everyone regardless. The gap between them within a trial is a preview of the larger gap between a trial and a population, and it is why a figure quoted without its estimand is uninterpretable.
What drives discontinuation
Cost, gastrointestinal tolerability, supply, and the ordinary attrition of any chronic regimen. Dziewierz and colleagues examine the role of nutritional and lifestyle support alongside the pharmacology, which reflects a view that persistence is not solely a property of the drug but of what surrounds its use.
Why this is not a criticism of the compounds
Poor persistence is a feature of chronic treatment generally rather than of these drugs specifically. Mody and colleagues were examining the same questions for this class back in 2018. It sets an upper bound on population benefit, and knowing that bound is part of reading the trial literature rather than an argument against it.
Frequently asked questions
What is the difference between adherence and persistence?
Adherence is taking treatment as directed while on it; persistence is still being on it later. Someone can be adherent for months and then stop.
Why does persistence matter so much for obesity?
The condition is chronic and stopping is followed by weight regain, so benefit depends on continued treatment.
How does this relate to estimands?
The treatment-policy estimand counts everyone including those who stopped, which is the same distinction applied inside a trial.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDziewierz A et al., Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support. Nutrients 2026 (PMID 42280404)pubmed.ncbi.nlm.nih.gov
- PubMedMody R et al., Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Curr Med Res Opin 2018 (PMID 29271258)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why a Drug Works Less Well Than Its Trial SaidEfficacy is performance under trial conditions; effectiveness is what happens in practice. The gap is predictable, and it has identifiable causes.
- Why Weight Loss Can Restore OvulationObesity and insulin resistance disrupt ovulation, particularly in PCOS. Reversing them can restore fertility - which is a documented effect, not a rumour.
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it - by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.
- Why Age Changes the CalculationThe same weight reduction carries different consequences at 75 than at 45. Lean mass, bone and nutritional intake all sit differently.